The Phase III MITIGATE trial demonstrated that Uplizna (inebilizumab) significantly reduces the risk of flares, lowers ...

In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be ...

Amgen AMGN reported the latest data from the phase III MINT study that evaluated the rare disease drug Uplizna (inebilizumab) for label expansion in generalized myasthenia gravis (gMG) indication.

72.3% of AChR+ patients on Uplizna saw a ≥3-point MG-ADL score improvement vs. 45.2% on placebo. Uplizna is under FDA priority review for IgG4-related disease with a PDUFA date of April 3.

Among the AChR+ patients in the Uplizna group, 69.2% improved by ≥3 points in the QMG score, compared to 41.8% in the placebo group.1 No new safety signals were identified. The overall TEAE ...

Amgen AMGN reported the latest data from the phase III MINT study that evaluated the rare disease drug Uplizna (inebilizumab) ...

Amgen (NASDAQ:AMGN), a prominent player in the biotechnology industry with a market capitalization of $167.88 billion, has announced results from the Phase 3 MINT trial of UPLIZNA® (inebilizumab ...

Data from the Phase III MINT trial found that Uplizna demonstrated a greater reduction in Myasthenia Gravis Activities of Daily Living score compared to placebo at week 26. Results from the Phase III ...

Amgen has shared new data from a late-stage trial of its B cell-depleting therapy Uplizna (inebilizumab-cdon) in adults with the rare autoimmune disorder generalised myasthenia gravis (gMG). The phase ...